COGNUTRIN in Breast Cancer Survivors

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 30, 2014

Primary Completion Date

April 5, 2017

Study Completion Date

May 2, 2018

Conditions
Breast Cancer
Interventions
DRUG

VitaBlue™

"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."

OTHER

Placebo

"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."

DRUG

Lovaza®

"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
collaborator

Gateway for Cancer Research

OTHER

collaborator

University of South Florida

OTHER

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01823991 - COGNUTRIN in Breast Cancer Survivors | Biotech Hunter | Biotech Hunter